ArticleInternational urology and nephrology2017
Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.
Article in International urology and nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Role of hydroxychloroquine in primary glomerular disease - a systematic review and meta-analysis of the current evidence.BMC nephrology · 2025Pooled it
- Quantitative Comparison of the Clinical Efficacy of 6 Classes Drugs for IgA Nephropathy: A Model-Based Meta-Analysis of Drugs for Clinical Treatments.Frontiers in immunology · 2022Pooled it
- Hydroxychloroquine in IgA nephropathy: a systematic review.Renal failure · 2021Pooled it
- Hydroxychloroquine use in pediatric IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Alport syndrome complicated with IgA nephropathy: a case report.Frontiers in medicine · 2026Article
- Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.BMC nephrology · 2025Article
- Hydroxychloroquine sulfate for IgA nephropathy: mechanisms and therapeutic potential in improving proteinuria and alleviating disease progression - a literature review.BMC nephrology · 2025Review
- Early reduction in total cholesterol to high-density lipoprotein cholesterol ratio predicts hydroxychloroquine efficacy in treating IgA nephropathy.Renal failure · 2024Article
- Mechanical forces inducing oxaliplatin resistance in pancreatic cancer can be targeted by autophagy inhibition.Communications biology · 2024Article
- Drugs in Development to Treat IgA Nephropathy.Drugs · 2024Review
- Article
- The role of toll-like receptors (TLRs) and their therapeutic applications in glomerulonephritis.International urology and nephrology · 2023Review
- Hydroxychloroquine in nephrology: current status and future directions.Journal of nephrology · 2023Review
- IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Effects of hydroxychloroquine on proteinuria in membranous nephropathy.Journal of nephrology · 2022Article
- The Effect of Hydroxychloroquine on Residual Proteinuria in Patients With Immunoglobulin A Nephropathy: A Retrospective Study Based on Propensity Score Matching.Frontiers in medicine · 2022Article
- Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective.Cardiovascular research · 2021Review
- Current treatment of IgA nephropathy.Seminars in immunopathology · 2021Review
- Increasing prescription of renin-angiotensin-aldosterone system blockers associated with improved kidney prognosis in Korean IgA nephropathy patients.Clinical kidney journal · 2021Article
- Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.International journal of nephrology and renovascular disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDendritic cells, Toll-like receptor (TLR), interleukin-6 (IFN-α), interferon-alpha (IFN-α) and tumor necrosis factor-alpha (TNF-α) play an important role in the pathogenesis of IgA nephropathy (IgAN). Hydroxychloroquine (HCQ) is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting DCs, reduced production of cytokines including IFN-α,IL-6 and TNF-α. We evaluated the efficacy of HCQ in reducing proteinuria in patients with IgAN.
methodsTwenty-eight IgAN patients with persistent proteinuria (0.5-2.0 g/24 h) despite treatment with losartan for 3 months were matched to receive HCQ and losartan (group 1) or continue losartan therapy (group 2) for 24 weeks. The primary end point of this prospective, paired case-control study was reduction of proteinuria by 50% or more over entry level.
resultsSix patients (42.9%) in group one versus two patients (14.3%) in group 2 reach the primary end point (P = 0.004). By 24 weeks, the mean urinary protein excretion was 65.9 ± 25.5% (P = 0.002) and 95.3 ± 30.0% (P = 0.791) that of the corresponding baseline value in group 1 and group 2, respectively. Baseline proteinuria and histologic grades, blood pressure control and changes in serum creatinine and eGFR were not different between the two groups.
conclusionsIn selected patients with IgAN, HCQ is effective in ameliorating proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.